Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model.

Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L.

Am J Obstet Gynecol. 2008 Apr;198(4):433.e1-2. doi: 10.1016/j.ajog.2007.10.802. Epub 2008 Feb 1.

PMID:
18241815
[PubMed - indexed for MEDLINE]
2.

Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.

Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH.

Clin Pharmacol Ther. 2005 Jun;77(6):515-28.

PMID:
15961983
[PubMed - indexed for MEDLINE]
3.

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.

Fung HB, Guo Y.

Clin Ther. 2004 Mar;26(3):352-78. Review.

PMID:
15110129
[PubMed - indexed for MEDLINE]
4.

Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.

de Requena DG, Bonora S, Castagna A, Hasson H, Marucco DA, D'Avolio A, Sciandra M, Trentini L, Calcagno A, Lazzarin A, Di Perri G.

J Antimicrob Chemother. 2008 Aug;62(2):384-7. doi: 10.1093/jac/dkn192. Epub 2008 May 16.

PMID:
18487231
[PubMed - indexed for MEDLINE]
Free Article
5.

Enfuvirtide: from basic investigations to current clinical use.

Joly V, Jidar K, Tatay M, Yeni P.

Expert Opin Pharmacother. 2010 Nov;11(16):2701-13. doi: 10.1517/14656566.2010.522178. Review.

PMID:
20977403
[PubMed - indexed for MEDLINE]
6.

Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.

Mohanty U, Dixit NM.

J Theor Biol. 2008 Apr 7;251(3):541-51. doi: 10.1016/j.jtbi.2007.12.017. Epub 2007 Dec 28.

PMID:
18258267
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Drug profile: enfuvirtide (Fuzeon, ENF, T-20).

Pham PA.

Hopkins HIV Rep. 2003 May;15(3):1-2. No abstract available.

PMID:
12809104
[PubMed - indexed for MEDLINE]
8.

[Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics].

Raffi F.

Med Mal Infect. 2004 Sep;34 Spec No 1:3-7. Review. French.

PMID:
15742549
[PubMed - indexed for MEDLINE]
9.

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss N, Patel IH.

J Clin Pharmacol. 2004 Jul;44(7):793-803.

PMID:
15199084
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.

Bellibas SE, Siddique Z, Dorr A, Bertasso A, Sista P, Kolis SJ, Cotler S, Delora P; T20-310/NV16056 Study Group.

Pediatr Infect Dis J. 2004 Dec;23(12):1137-41.

PMID:
15626952
[PubMed - indexed for MEDLINE]
11.

A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).

Manfredi R, Sabbatani S.

Curr Med Chem. 2006;13(20):2369-84. Review.

PMID:
16918361
[PubMed - indexed for MEDLINE]
12.

Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Vinot C, Gavard L, Tréluyer JM, Manceau S, Courbon E, Scherrmann JM, Declèves X, Duro D, Peytavin G, Mandelbrot L, Giraud C.

Antimicrob Agents Chemother. 2013 Mar;57(3):1415-20. doi: 10.1128/AAC.01821-12. Epub 2013 Jan 7.

PMID:
23295922
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.

Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB; Pediatric AIDS Clinical Trial Group (PACTG) Study P1005 Investigators.

Clin Pharmacol Ther. 2003 Dec;74(6):569-80.

PMID:
14663459
[PubMed - indexed for MEDLINE]
14.

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.

Cooper DA, Lange JM.

Lancet Infect Dis. 2004 Jul;4(7):426-36. Review.

PMID:
15219553
[PubMed - indexed for MEDLINE]
15.

Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.

Tebas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I, Chiu YY, Evans C, Rowell L, Salgo M.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):342-5.

PMID:
18091608
[PubMed - indexed for MEDLINE]
16.

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.

Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A; T20-310 Study Group.

Pediatr Infect Dis J. 2007 Sep;26(9):799-805.

PMID:
17721374
[PubMed - indexed for MEDLINE]
17.
18.

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.

Hardy H, Skolnik PR.

Pharmacotherapy. 2004 Feb;24(2):198-211.

PMID:
14998221
[PubMed - indexed for MEDLINE]
19.

Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.

Zhang X, Lin T, Bertasso A, Evans C, Dorr A, Kolis SJ, Salgo M, Patel I; T20-310/NV16056 Study Group.

J Clin Pharmacol. 2007 Apr;47(4):510-7.

PMID:
17389560
[PubMed - indexed for MEDLINE]
20.

Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.

Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, Derdeyn CA.

J Virol. 2004 Jul;78(14):7582-9.

PMID:
15220433
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk